Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Neuroblastoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The neuroblastoma market has witnessed significant growth, projected to expand from $3.14 billion in 2025 to $3.32 billion in 2026, with a CAGR of 5.8%. Factors driving this growth include an increase in pediatric neuroblastoma cases and advancements in treatment modalities, including chemotherapy and immunotherapy vaccines. Clinical diagnostic capabilities have also improved, leading to better early detection and heightened awareness of childhood cancer symptoms. Looking ahead, the neuroblastoma market is set to continue its upward trajectory, reaching $4.12 billion by 2030 at a CAGR of 5.5%. This growth is bolstered by ongoing research in targeted therapy, increased investments in cell therapy products, and adoption of precision oncology methods. Innovations such as advanced diagnostic imaging and pediatric immunotherapy solutions are key contri
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year [Yahoo! Finance]Yahoo! Finance
- CLO Sells LGND 5,000 Shares for $1.0 Million [Yahoo! Finance]Yahoo! Finance
- Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know [Yahoo! Finance]Yahoo! Finance
- Ligand Advances Strategic Growth with Expanded and Strengthened Business Development TeamGlobeNewswire
- Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $270.00 to $276.00. They now have a "buy" rating on the stock.MarketBeat
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/1/26 - Form 144
- LGND's page on the SEC website